Andrew D Hislop

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6951294/publications.pdf

Version: 2024-02-01

35 papers	3,838 citations	236925 25 h-index	361022 35 g-index
36 all docs	36 docs citations	36 times ranked	4528 citing authors

#	Article	IF	Citations
1	Cellular Responses to Viral Infection in Humans: Lessons from Epstein-Barr Virus. Annual Review of Immunology, 2007, 25, 587-617.	21.8	668
2	The Immunology of Epstein-Barr Virusâ€“Induced Disease. Annual Review of Immunology, 2015, 33, 787-821.	21.8	416
3	Herpesvirus-Specific CD8 T Cell Immunity in Old Age: Cytomegalovirus Impairs the Response to a Coresident EBV Infection. Journal of Immunology, 2004, 173, 7481-7489.	0.8	319
4	Epitope-specific Evolution of Human CD8+ T Cell Responses from Primary to Persistent Phases of Epstein-Barr Virus Infection. Journal of Experimental Medicine, 2002, 195, 893-905.	8.5	267
5	EBV-Specific CD8+ T Cell Memory: Relationships Between Epitope Specificity, Cell Phenotype, and Immediate Effector Function. Journal of Immunology, 2001, 167, 2019-2029.	0.8	194
6	A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. Journal of Experimental Medicine, 2007, 204, 1863-1873.	8.5	154
7	Memory T Cells Constitute a Subset of the Human CD8+CD45RA+Pool with Distinct Phenotypic and Migratory Characteristics. Journal of Immunology, 2001, 167, 212-220.	0.8	150
8	Epstein-Barr virusâ€“specific CD8+ T cells that re-express CD45RA are apoptosis-resistant memory cells that retain replicative potential. Blood, 2002, 100, 933-940.	1.4	140
9	CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. Journal of Experimental Medicine, 2005, 201, 349-360.	8.5	135
10	Inherited CD70 deficiency in humans reveals a critical role for the CD70â€“CD27 pathway in immunity to Epstein-Barr virus infection. Journal of Experimental Medicine, 2017, 214, 73-89.	8.5	122
11	Cellular immune controls over Epsteinâ€“Barr virus infection: new lessons from the clinic and the laboratory. Trends in Immunology, 2014, 35, 159-169.	6.8	121
12	Tonsillar homing of Epstein-Barr virus-specific CD8+ T cells and the virus-host balance. Journal of Clinical Investigation, 2005, 115, 2546-2555.	8.2	107
13	Molecular Pathogenesis of EBV Susceptibility in XLP as Revealed by Analysis of Female Carriers with Heterozygous Expression of SAP. PLoS Biology, 2011, 9, e1001187.	5.6	100
14	Impaired Epstein-Barr virusâ€“specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM familyâ€“positive B-cell targets. Blood, 2010, 116, 3249-3257.	1.4	92
15	The Effects of Acute Malaria on Epstein-Barr Virus (EBV) Load and EBV-Specific T Cell Immunity in Gambian Children. Journal of Infectious Diseases, 2009, 199, 31-38.	4.0	86
16	Stage-Specific Inhibition of MHC Class I Presentation by the Epstein-Barr Virus BNLF2a Protein during Virus Lytic Cycle. PLoS Pathogens, 2009, 5, e1000490.	4.7	80
17	Selective accumulation of virus-specific CD8+ T cells with unique homing phenotype within the human bone marrow. Blood, 2008, 112, 3293-3302.	1.4	78
18	The Epstein-Barr Virus-Encoded BILF1 Protein Modulates Immune Recognition of Endogenously Processed Antigen by Targeting Major Histocompatibility Complex Class I Molecules Trafficking on both the Exocytic and Endocytic Pathways. Journal of Virology, 2011, 85, 1604-1614.	3.4	74

#	Article	IF	Citations
19	Compartmentalization of Total and Virus-Specific Tissue-Resident Memory CD8+ T Cells in Human Lymphoid Organs. PLoS Pathogens, 2016, 12, e1005799.	4.7	74
20	Early Virological and Immunological Events in Asymptomatic Epstein-Barr Virus Infection in African Children. PLoS Pathogens, 2015, 11, e1004746.	4.7	64
21	Asymptomatic Primary Infection with Epstein-Barr Virus: Observations on Young Adult Cases. Journal of Virology, 2017, 91, .	3.4	56
22	Cooperation between Epstein-Barr Virus Immune Evasion Proteins Spreads Protection from CD8+ T Cell Recognition across All Three Phases of the Lytic Cycle. PLoS Pathogens, 2014, 10, e1004322.	4.7	47
23	Activation of DNA Damage Response Pathways during Lytic Replication of KSHV. Viruses, 2015, 7, 2908-2927.	3.3	40
24	EBV Protein BNLF2a Exploits Host Tail-Anchored Protein Integration Machinery To Inhibit TAP. Journal of Immunology, 2011, 186, 3594-3605.	0.8	39
25	T-cell immunity to Kaposi sarcomaâ€“associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells. Blood, 2012, 119, 2083-2092.	1.4	29
26	T-Cell Responses to EBV. Current Topics in Microbiology and Immunology, 2015, 391, 325-353.	1.1	25
27	Cytokine-Mediated Loss of Blood Dendritic Cells During Epstein-Barr Virusâ€“Associated Acute Infectious Mononucleosis: Implication for Immune Dysregulation. Journal of Infectious Diseases, 2015, 212, 1957-1961.	4.0	22
28	Proteome-wide analysis of CD8+ T cell responses to EBV reveals differences between primary and persistent infection. PLoS Pathogens, 2018, 14, e1007110.	4.7	22
29	Impaired Epstein-Barr Virus-Specific Neutralizing Antibody Response during Acute Infectious Mononucleosis Is Coincident with Global B-Cell Dysfunction. Journal of Virology, 2015, 89, 9137-9141.	3.4	21
30	CD8+ T cell immunity to Epstein-Barr virus and Kaposiâ€™s sarcoma-associated herpes virus. Seminars in Cancer Biology, 2008, 18, 416-422.	9.6	18
31	Upregulation of Interleukin 7 Receptor Alpha and Programmed Death 1 Marks an Epitope-Specific CD8⁺T-Cell Response That Disappears following Primary Epstein-Barr Virus Infection. Journal of Virology, 2009, 83, 9068-9078.	3.4	18
32	Kaposi's Sarcoma-Associated Herpesvirus-Encoded Viral IRF3 Modulates Major Histocompatibility Complex Class II (MHC-II) Antigen Presentation through MHC-II Transactivator-Dependent and -Independent Mechanisms: Implications for Oncogenesis. Journal of Virology, 2013, 87, 5340-5350.	3.4	18
33	Early virological and immunological events in Epsteinâ€“Barr virus infection. Current Opinion in Virology, 2015, 15, 75-79.	5.4	18
34	Primary B Lymphocytes Infected with Kaposi's Sarcoma-Associated Herpesvirus Can Be Expanded In Vitro and Are Recognized by LANA-Specific CD4 ⁺ T Cells. Journal of Virology, 2016, 90, 3849-3859.	3.4	17
35	Azidothymidine Sensitizes Primary Effusion Lymphoma Cells to Kaposi Sarcoma-Associated Herpesvirus-Specific CD4+ T Cell Control and Inhibits vIRF3 Function. PLoS Pathogens, 2016, 12, e1006042.	4.7	5